# Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

> **NCT03809624** · PHASE1 · TERMINATED · sponsor: **Inhibrx Biosciences, Inc** · enrollment: 160 (actual)

## Conditions studied

- Metastatic Solid Tumors
- Non-small Cell Lung Cancer
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Renal Cell Carcinoma
- Esophageal Adenocarcinoma
- Nasopharyngeal Carcinoma
- Oropharyngeal Carcinoma

## Interventions

- **DRUG:** INBRX-105 - PDL1x41BB antibody
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03809624
- **Lead sponsor:** Inhibrx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-30
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-10-03
- **Target enrollment:** 160 (ACTUAL)
- **Why stopped:** Program terminated due to lack of meaningful efficacy signal.
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809624, "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03809624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*